# Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

> **NCT06999902** · PHASE2,PHASE3 · RECRUITING · sponsor: **Praxis Precision Medicines** · enrollment: 230 (estimated)

## Conditions studied

- Focal Seizure

## Interventions

- **DRUG:** 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06999902
- **Lead sponsor:** Praxis Precision Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2025-11-24
- **Final completion:** 2025-12-08
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999902, "Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06999902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*